Present in pre-malignant mammary lesions and tumors, CA is more prevalent in triple-negative (estrogen and progesterone receptor-negative and non-amplified for Her2, or ER-PR-Her2-) breast cancer subtype and correlates with stage, grade, and poor survival of breast cancer patients29–36. This evidence concerns the gene PGR and breast carcinoma.